Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL5147 Target Snapshot

Ephrin type-B receptor 4 · SINGLE PROTEIN · Homo sapiens

Back to Search Search this target Browse approvals Evidence Card
2,536Compounds
427Assays
21Approved Drugs
1,941.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Research home Demo workspace
Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Ephrin type-B receptor 4 shows late clinical disease relevance led by non-small cell lung carcinoma. 5 more disease programs remain visible in the same review block. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt P54760. Start with non-small cell lung carcinoma, then reuse UniProt P54760 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with non-small cell lung carcinoma, then reuse UniProt P54760 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13 1 linked drug
Open source guide
Disease program
non-small cell lung carcinoma

Ephrin type-B receptor 4 shows late clinical disease relevance led by non-small cell lung carcinoma. 5 more disease programs remain visible in the same review block. 1 linked drug remains visible in the same block.

Start review with non-small cell lung carcinoma because it currently carries late clinical support. Linked drugs include TESEVATINIB. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Late clinical Open Targets-ready proxy 1 linked drug
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Ephrin type-B receptor 4 as ChEMBL target CHEMBL5147, mapped to UniProt P54760. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Ephrin type-B receptor 4
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL5147
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P54760
Ephrin type-B receptor 4
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Ephrin type-B receptor 4 is the right protein anchor across sources, using UniProt P54760 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why non-small cell lung carcinoma is currently framed as late clinical support. It currently carries 1 linked drug in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

Preferred NameEphrin type-B receptor 4
Target TypeSINGLE PROTEIN
OrganismHomo sapiens
UniProtP54760
ChEMBL ↗ UniProt ↗ NCBI Protein ↗

Next Actions

SearchRun a focused querySearch the database using this target name as the starting context. ApprovalsCheck approved moleculesSee which approved drugs connect back to this target and its surrounding signal space. FeedScan papers & updatesStay in the project thread while checking recent papers and platform updates.
UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelEphrin type-B receptor 4
UniProt AccessionP54760
Component TypeProtein
Sequence Length987 aa

Ephrin type-B receptor 4

Source · UniProt accession via ChEMBL component mapping
UniProt Context ↗
Review Cue

How to read this target

Review this target as Ephrin type-B receptor 4, mapped to UniProt P54760. Sequence length is 987 aa.

Mapped IDP54760
Review nameEphrin type-B receptor 4
OrganismHomo sapiens
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Late clinical Open Targets-ready proxy

Ephrin type-B receptor 4 shows late clinical disease relevance led by non-small cell lung carcinoma. 5 more disease programs remain visible in the same review block.

Late clinical Phase III
non-small cell lung carcinoma
1 linked drug · 1 direct · 1 efficacy
Linked drugTESEVATINIB
Clinical signal Phase II
Autosomal dominant polycystic kidney disease
1 linked drug · 1 direct · 1 efficacy
Linked drugTESEVATINIB
Clinical signal Phase II
brain neoplasm
1 linked drug · 1 direct · 1 efficacy
Linked drugTESEVATINIB
Clinical signal Phase II
choroidal neovascularization
1 linked drug · 1 direct · 1 efficacy
Linked drugTG100-801
Clinical signal Phase II
glioblastoma multiforme
1 linked drug · 1 direct · 1 efficacy
Linked drugTESEVATINIB
Clinical signal Phase II
macular degeneration
1 linked drug · 1 direct · 1 efficacy
Linked drugTG100-801
Source · ChEMBL drug mechanism + indication proxy
ChEMBL target record ↗
Review Cue

How to read disease relevance

Start review with non-small cell lung carcinoma because it currently carries late clinical support. Linked drugs include TESEVATINIB. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseasenon-small cell lung carcinoma
Strongest levelLate clinical
Block modeOpen Targets-ready proxy
Clinical Profile

Clinical Phase Distribution

21
Approved
8
Phase III
17
Phase II
6
Phase I
Assay Mix

Activity Type Distribution

IC501,541.0
KI6.0
EC504.0
KD390.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL4100979 9.89 IC50 0.13 Preclinical
CHEMBL4469077 9.8 IC50 0.16 Preclinical
CHEMBL1336 9.7 IC50 0.2 Approved
CHEMBL4459732 9.6 IC50 0.25 Preclinical
CHEMBL4069517 9.57 IC50 0.27 Preclinical
CHEMBL4456738 9.49 IC50 0.32 Preclinical
CHEMBL5416410 9.47 Kd 0.34 Approved
CHEMBL241682 9.4 IC50 0.4 Preclinical
CHEMBL4519953 9.36 IC50 0.44 Preclinical
CHEMBL1270280 9.05 IC50 0.9 Preclinical
Distribution

pChEMBL Value Distribution

78
5.0
120
5.5
328
6.0
100
6.5
262
7.0
79
7.5
47
8.0
23
8.5
8
9.0
7
9.5
pChEMBL
Approved Drugs

Approved Drugs

TIVOZANIB
CHEMBL1289494
Approved 2017
Properties Compare Identifier
BOSUTINIB
CHEMBL288441
Approved 2012
Properties Compare Identifier
CRIZOTINIB
CHEMBL601719
Approved 2011
Properties Compare Identifier
VANDETANIB
CHEMBL24828
Approved 2011
Properties Compare Identifier
NILOTINIB
CHEMBL255863
Approved 2007
Properties Compare Identifier
DASATINIB
CHEMBL5416410
Approved 2006
Properties Compare Identifier
DASATINIB ANHYDROUS
CHEMBL1421
Approved 2006
Properties Compare Identifier
SORAFENIB
CHEMBL1336
Approved 2005
Properties Compare Identifier
GEFITINIB
CHEMBL939
Approved 2003
Properties Compare Identifier
Assay Landscape

Assay Landscape

427
Total Assays
1,058
Tested Compounds
1
Assay Types
Binding — 427 assays, 1,058 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 332 700 6.3
cell-based format 48 100 6.8
assay format 35 232 7.1
subcellular format 12 26 6.3

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine